Danaher Corporation (DHR)
NYSE:DHR
Want to see DHR full AI Analyst Report?
DHR Stock Chart & Stats
$194.75
-$1.72(-0.72%)
At close: 4:00 PM EST
$194.75
-$1.72(-0.72%)
Day’s Range― - ―
52-Week Range$160.93 - $242.80
Previous CloseN/A
Volume816.38K
Average Volume (3M)5.27M
Market Cap
$124.65B
Enterprise Value$142.07B
Total Cash (Recent Filing)$5.70B
Total Debt (Recent Filing)$18.48B
Price to Earnings (P/E)33.8
Beta0.84
Next Earnings
Jul 28, 2026EPS Estimate
1.83Next Dividend Ex-DateN/A
Dividend Yield0.53%
Share Statistics
EPS (TTM)5.19
Shares Outstanding707,770,600
10 Day Avg. Volume4,503,966
30 Day Avg. Volume5,274,540
Financial Highlights & Ratios
PEG Ratio-9.18
Price to Book (P/B)3.08
Price to Sales (P/S)6.59
P/FCF Ratio30.78
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue5.73
Enterprise Value/Gross Profit9.45
Enterprise Value/Ebitda21.24
Forecast
1Y Price Target
$230.32Price Target Upside18.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)8.44
Revenue Forecast (FY)$25.47B
Bulls Say, Bears Say
Bulls Say
Robust Cash GenerationSustained high operating and free cash flow provides durable internal funding for R&D, consumables capacity, share actions and M&A without overreliance on external markets. Strong cash conversion improves resilience to cyclical revenue swings and supports multi-year strategic investments.
Recurring Consumables And High MarginsA large installed base and high consumables pull-through underpin recurring revenue and gross margins. Durable consumables demand in bioprocessing and diagnostics supports predictable revenue streams and pricing power, cushioning capital-equipment cyclicality over the medium term.
Balance Sheet And Funding FlexibilityProactive multi-currency financing and a manageable debt profile (debt/equity ~0.35) give Danaher structural capacity for accretive M&A and working-capital needs. Access to diversified funding reduces execution risk for strategic deals and supports long-term capital allocation plans.
Bears Say
China Diagnostics Pricing HeadwindsVolume-based procurement and reimbursement changes in China represent structural policy risk that can durably compress revenue and margins in Diagnostics. Given China’s scale, sustained policy-driven pricing pressure could lower regional earnings and slow global segment recovery for quarters to years.
Respiratory Seasonality And Revenue VolatilityLarge seasonal swings in respiratory testing create recurring top-line variability and pull-through uncertainty for instrument-related consumables. This cyclical revenue can depress near-term growth metrics and complicate forecasting and capacity planning across Diagnostics for multiple seasons ahead.
Stepped-down Profitability And Lower ReturnsMaterial decline in ROE and net margins versus prior peaks suggests lower structural earnings power. If profitability remains below historical norms, capital efficiency and ability to generate high incremental returns on future M&A or organic investments will be constrained over the medium term.
Danaher News
DHR FAQ
What was Danaher Corporation’s price range in the past 12 months?
Danaher Corporation lowest stock price was $160.93 and its highest was $242.80 in the past 12 months.
What is Danaher Corporation’s market cap?
Danaher Corporation’s market cap is $124.65B.
When is Danaher Corporation’s upcoming earnings report date?
Danaher Corporation’s upcoming earnings report date is Jul 28, 2026 which is in 54 days.
How were Danaher Corporation’s earnings last quarter?
Danaher Corporation released its earnings results on Apr 21, 2026. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.935 by $0.125.
Is Danaher Corporation overvalued?
According to Wall Street analysts Danaher Corporation’s price is currently Undervalued.
Does Danaher Corporation pay dividends?
Danaher Corporation pays a Quarterly dividend of $0.32 which represents an annual dividend yield of 0.53%. See more information on Danaher Corporation dividends here
What is Danaher Corporation’s EPS estimate?
Danaher Corporation’s EPS estimate is 1.83.
How many shares outstanding does Danaher Corporation have?
Danaher Corporation has 707,770,600 shares outstanding.
What happened to Danaher Corporation’s price movement after its last earnings report?
Danaher Corporation reported an EPS of $2.06 in its last earnings report, beating expectations of $1.935. Following the earnings report the stock price went down -0.491%.
Which hedge fund is a major shareholder of Danaher Corporation?
Currently, no hedge funds are holding shares in DHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Danaher Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$230.32 (18.26% Upside)
$230.32 (18.26% Upside)
Blogger Sentiment
Bullish
DHR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $237.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.29%
12-Months-Change
Fundamentals
Return on Equity
7.06%
Trailing 12-Months
Asset Growth
5.60%
Trailing 12-Months
Company Description
Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
DHR Company Deck
DHR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted solid execution: strong earnings growth (+9.5% adjusted EPS), margin expansion, robust free cash flow, a raised full-year EPS range, clear momentum in bioprocessing (consumables growth and >30% equipment order growth), and constructive China trends. Management acknowledged near-term headwinds—chiefly a ~25% drop in respiratory revenue, Diagnostics weakness in China from VBP/reimbursement, and seasonally lower Q2 margins—but provided unchanged core revenue guidance (3%–6%), articulated remediation (DBS and identified Masimo synergies), and emphasized balance sheet strength and active M&A. Overall, positives (earnings, cash generation, bioprocessing momentum, product wins, M&A synergies) materially outweigh the moderated but manageable negatives (respiratory seasonality, China policy headwinds and instrument softness).View all DHR earnings summariesDHR Revenue Breakdown
29.68% Biotechnology
29.85% Life Sciences
40.46% Diagnostics
DHR Stock 12 Month Forecast
Average Price Target
$230.32
▲(18.26% Upside)
Technical Analysis
Ownership Overview
3.90% Insiders
26.49% Mutual Funds
22.12% Other Institutional Investors
27.21% Public Companies and Individual Investors